



IN REPLY REFER TO  
MEDCE-OH

HEADQUARTERS  
DEPARTMENT OF THE ARMY  
OFFICE OF THE SURGEON GENERAL  
WASHINGTON 25, D. C.

10-3997-3  
8279  
NB  
14 October 1959

Isotopes Branch  
Division of Licensing and Regulation  
U. S. Atomic Energy Commission  
Washington 25, D. C.

21236  
10-3997-2

Gentlemen:


As requested in your letter of 23 September 1959, the original of page 3, Form AEC-313a is submitted in support of the application in behalf of Doctor Francis M. Fesmire, Third United States Army Medical Laboratory, Fort McPherson, Georgia.

Sincerely,

Charles W. Kraul.

1 Incl  
Form AEC-313a

CHARLES W. KRAUL  
Lt Colonel, MC  
Chief, Occupational Health Branch  
Preventive Medicine Division



00/2

**APPLICATION FOR BYPRODUCT MATERIAL LICENSE**  
**SUPPLEMENT A—HUMAN USE**

Form approved.  
Budget Bureau No. 38-R080.1

This page may be completed by the physician's preceptor (if any) in the medical use of radioisotopes. When the information is not furnished by the preceptor, the name and present address of the preceptor (if any) should be shown in item 12 below.

9. (a) USING PHYSICIAN'S NAME

(b) NAME AND ADDRESS OF APPLICANT (If different from 9(a))

**FRANCIS M. FESMIRE, M. D.**  
**Third US Army Medical Lab**  
**Fort McPherson, Georgia**

Same as (a)

**10. CLINICAL TRAINING AND EXPERIENCE OF PHYSICIAN WHO WILL USE BYPRODUCT MATERIAL**

(A) ISOTOPE	(B) CONDITION(S) DIAGNOSED OR TREATED	(C) NUMBER OF CASES	(D) TYPE OF PARTICIPATION FOR ALL CASES IN COLUMN D (circle applicable num- bers of items in accordance with key set forth below)
I-131	Diagnosis of thyroid function	28	(1)(2)(3)(4)
	Treatment of hyperthyroidism		1 2 3 4
	Treatment of thyroid cancer		1 2 3 4
	Treatment of cardiac conditions		1 2 3 4
	Brain tumor localization		1 2 3 4
	Blood determinations		1 2 3 4
	Others:		1 2 3 4
P-32 Soluble	Treatment of polycythemia and leukemia		1 2 3 4
	Brain tumor localization		1 2 3 4
	Treatment of bone metastases		1 2 3 4
	Others:		1 2 3 4
P-32 CrPO <sub>4</sub>	Treatment of prostatic cancer		1 2 3 4
	Treatment of cervical cancer		1 2 3 4
	Treatment of pleural effusions and/or ascites		1 2 3 4
	Others:		1 2 3 4
Au-198 Colloid	Treatment of prostatic cancer		1 2 3 4
	Treatment of cervical cancer		1 2 3 4
	Treatment of pleural effusions and/or ascites		1 2 3 4
	Others:		1 2 3 4
Cr-51	Blood determinations		1 2 3 4
	Others:		1 2 3 4
Other Isotopes	Cobalt-60 and Cobalt-58 Pernicious anemia	2	(1)(2)(3)(4)
			1 2 3 4
			1 2 3 4

Key to above numbers (column D)

Active Participation and Discussion

1. Examination of patients to determine suitability for radioisotope diagnosis and/or treatment and recommendations on dosage to be prescribed.
2. Collaboration in calibration and administration of dosages including related measurements and plotting of data.
3. Active period of training and experience of sufficient duration to permit followup of patients through treatment and posttreatment period including reevaluation as to effectiveness and complications.
4. Study and discussion of case histories to establish most efficacious diagnostic and/or therapeutic techniques for this radioisotope use.

11. TOTAL NUMBER OF HOURS OF PARTICIPATION IN CLINICAL TRAINING 75 hours

12. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OR GUIDANCE OF

**C. W. Freeman, M.D.**

**Abbott Hospital, Minneapolis, Minn.**

**Carl J. Lind, M. D., Col., MC, Third US Army Medical Lab.,**

(Name of physician (preceptor))

**Ft. McPherson, Ga.**

(Signature)

*C. W. Freeman by Carl J. Lind*  
*Carl J. Lind*  
(Signature)

**APPLICATION FOR BYPRODUCT MATERIAL LICENSE**  
**SUPPLEMENT A—HUMAN USE**

Form approved.  
Budget Bureau No. 38-R080.1

This page may be used for providing additional information.

AEC-313

Item No. 14 Continued: Radioisotope compounds are received precalibrated from Abbott Laboratories, stored in a lead brick lined iron safe in a locked room until ready for use. The material is monitored from safe to patient. The laboratory is monitored each day isotopes are used for spills or leaks.

Item No. 15 Continued: Waste material is kept in a safe room until it has deteriorated to a safe level and then discarded down the sink well diluted with water from the tap, into the common sewerage system.